Open Access<p>Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC</p>
Author(s) -
Naoko Katsurada,
Motoko Tachihara,
Yukihisa Hatakeyama,
K Koyama,
Masako Yumura,
Tatsunori Kiriu,
Ryota Dokuni,
Daisuke Hazama,
Seiki Tokunaga,
Daisuke Tamura,
Kyosuke Nakata,
Masatsugu Yamamoto,
Hiroshi Kamiryo,
Kazuyuki Kobayashi,
Yugo Tanaka,
Yoshimasa Maniwa,
Yoshihiro Nishimura
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s239647
Subject(s) - medicine , carboplatin , regimen , neutropenia , chemotherapy , oncology , paclitaxel , clinical endpoint , lung cancer , chemotherapy regimen , urology , febrile neutropenia , adjuvant , cisplatin , gastroenterology , randomized controlled trial
Adjuvant chemotherapy with cisplatin (CDDP) plus vinorelbine is the standard regimen for the treatment of non-small cell lung cancer (NSCLC). However, CDDP elicits severe toxic effects, including emesis, neurotoxicity, and renal damage; carboplatin (CBDCA) may be a feasible alternative for CDDP-unfit patients. CBDCA plus paclitaxel (PTX) adjuvant chemotherapy showed a survival benefit for patients with stage IB tumors >4 cm in size, while CBDCA plus nanoparticle albumin-bound (nab)-PTX showed greater efficacy and lower neurotoxicity than CBDCA plus PTX in advanced NSCLC. Here, we investigated the feasibility of using CBDCA plus nab-PTX as adjuvant chemotherapy for NSCLC.